Ma. Kurz et al., CARDIOPROTECTION WITH A NOVEL ADENOSINE REGULATING AGENT MEDIATED BY INTRAVASCULAR ADENOSINE, European journal of pharmacology, 322(2-3), 1997, pp. 211-220
Adenosine is cardioprotective in models of myocardial stunning and inf
arction, but the precise compartment within the heart in which adenosi
ne elicits its cardioprotective effects has not been determined. The g
oals of the present study were to (i) investigate the effects of a nov
el adenosine regulating agent, GP531 amino-1-beta-D-(5-benzylamino-5-d
eoxyribofuranosyl on posts ischemic myocardial function, and (ii) exam
ine the contribution of endogenous adenosine in the intravascular and
interstitial compartments in mediating the beneficial effects. Pigs we
re instrumented for measurement of myocardial segment shortening, and
for sampling of coronary venous blood and myocardial interstitial flui
d for determination of adenosine concentration. Myocardial dysfunction
was induced by 4 x 8 min coronary occlusions, and recovery of regiona
l function was monitored for 2 h. In control pigs, function recovered
to 24 +/- 2% of baseline after 2 h. Treatment with GP531 improved func
tional recovery to 55 +/- 3%. GP531-mediated cardioprotection was prev
ented by adenosine receptor blockade with 8-sulfophenyltheophylline (2
3 +/- 2%). GP531 did not affect basal adenosine levels, but caused a 2
-fold greater increase in vascular adenosine concentration with ischem
ia (54.6 +/- 10.6 vs. 28.1 +/- 8.0 mu M in controls, P < 0.05). In con
trast, the interstitial adenosine concentration was not significantly
different in treated vs. untreated control pigs (9.4 +/- 3.9 vs. 15.0
+/- 1.3 mu M in controls). These data indicate that (1) GP531 improves
recovery of myocardial function following ischemia-reperfusion injury
via an adenosine receptor-dependent mechanism, and (2) the cardioprot
ection is associated with increased intravascular, but not interstitia
l, adenosine concentration during ischemia. Therefore, we conclude tha
t cardioprotection elicited by GP531-enhanced endogenous adenosine is
dependent on an intravascular site of action. (C) 1997 Elsevier Scienc
e B.V.